UPDATE: Stifel Starts Intellia Therapeutics (NTLA) at Buy

September 23, 2021 4:09 PM EDT
Get Alerts NTLA Hot Sheet
Price: $132.68 +1.41%

Rating Summary:
    17 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 48
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - September 23, 2021 4:13 PM EDT)

Stifel analyst Dae Gon Ha initiates coverage on Intellia Therapeutics (NASDAQ: NTLA) with a Buy rating and a price target of $173.00.

The analyst commented, "At $10B+ market cap with a Ph.1/2 asset (NTLA-2001), we are cognizant of investors' pushback on valuation. We also recognize the commercial challenges for both in vivo programs that, competitively speaking, need to be considered. However, as positive data continue to accrue, we still think some upside can be driven on '2001/'2002, while, more importantly, we see lead assets as sentinel programs towards broader in vivo editing. Additionally, we think lipid nanoparticle (LNP) delivery differentiates NTLA as the approach 1) affords flexibility in cargo size, and 2) potentiates combo editing (i.e., insertion) beyond the initial deletion programs. Understandably, stock performance near term may be '2001/'2002-related, but additional pillars of growth may be possible over the long term as nascent technologies (e.g., Cas9-deaminase) come to fruition with relevant comps in ~$B market cap range."

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $149.05 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Stifel